New Country Manager at AOP Health in Germany
Dirk Greshake is taking the helm at AOP Health in Germany as of April 2023.
(Vienna, 17.04.2023) The experienced manager Dirk Greshake, has been working in the pharmaceutical industry for 29 years and ten of those have been in management positions. He has played a key role in shaping the future of a number of businesses, from large publicly listed companies to smaller family-owned companies and start-ups. In his work at AOP Health in Germany, he has vowed to strengthen the company’s position as a provider of integrated therapies in the treatment of rare diseases and in intensive care medicine.
“The AOP Health Group focuses intensively on R&D and has therefore built up a strong portfolio. Our high scientific standards and commitment to manufacturing in Europe ensure that we are a reliable partner within the healthcare system. I feel I’ve been given a great opportunity to help shape this future.”
Creating structures, developing potential
One of Greshake’s main concerns is to create and shape the kinds of structures that determine a company’s success. He is also passionate about promoting the professional and personal development of the people he works with.
What attracted him to AOP Health was the company’s forward-looking portfolio, and the high standards it demands of its products.
“Dirk Greshake is the kind of person who gets the job done. As a growing company, we have found in him someone who will plan and orchestrate our future in Germany, one of the most important markets for us, in every area. We’re delighted to have been able to get him on board.”
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as the doctors and healthcare professionals treating them.
DI Isolde Fally